Compare AVTX & LOKV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVTX | LOKV |
|---|---|---|
| Founded | 2011 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.4M | 300.4M |
| IPO Year | 2015 | N/A |
| Metric | AVTX | LOKV |
|---|---|---|
| Price | $13.17 | $10.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $40.57 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 509.1K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $4.20 | $9.88 |
| 52 Week High | $24.27 | $11.46 |
| Indicator | AVTX | LOKV |
|---|---|---|
| Relative Strength Index (RSI) | 33.36 | 54.73 |
| Support Level | $9.09 | $10.24 |
| Resistance Level | $16.02 | N/A |
| Average True Range (ATR) | 1.16 | 0.02 |
| MACD | -0.51 | 0.00 |
| Stochastic Oscillator | 0.83 | 42.86 |
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Live Oak Acquisition Corp V is a blank check company.